Ioxilan
This non-ionic, low-osmolality iodinated contrast medium is used for urography, angiography, and CT imaging. It provides good visualization of blood vessels and body structures with a favorable tolerability profile due to its low osmolality. As with all iodinated contrast agents, patients should be monitored for allergic reactions and kidney function should be assessed.
Peso Molecular
791,1000 g/mol
LogP
-2,40
TPSA
180,00 Ų
Regra dos 5 de Lipinski
Reprovado
Mecanismo de Ação
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I
InChI
InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)
Molecular Formula
C18H24I3N3O8
HBD / HBA
7 / 8
Ligações Rotacionáveis
11
Átomos Pesados
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This non-ionic, low-osmolality iodinated contrast medium is used for urography, angiography, and CT imaging. It provides good visualization of blood vessels and body structures with a favorable tolerability profile due to its low osmolality. As with all iodinated contrast agents, patients should be monitored for allergic reactions and kidney function should be assessed.
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Yes, Ioxilan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201075. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3743. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ioxilan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ioxilan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ioxilan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ioxilan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ioxilan"></drugfyi-drug>